In the absence of a tumor, there was no significant change in the levels of TRP2-specific CD3+CD8+ T lymphocytes in the peripheral blood lymphocyte (PBL), suggesting that PMG5 had an influence on the TME rather than directly affecting the efficacy of the cancer vaccine (fig. Here, CD8A is linked to cancer.